{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010138","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.341887+00:00","generated_at":"2026-05-24T21:36:44.918250+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus reports Q4 loss per share $1.61; cash $5.8M; Decoy20 trial enrolls >20 patients","bullets":["Cash and equivalents $5.8M as of Dec 31, 2024; Jan 2025 private placement raised net $2.0M.","Entered $20M equity line with Yorkville in Feb 2025; expects cash runway into Q2 2025.","Phase 1 Decoy20 weekly dosing cohort >20 patients; early stable disease observed.","R&D expense Q4 2024 $2.5M vs $2.0M YoY; full-year $7.2M vs $7.6M.","Clinical supply agreement with BeiGene for tislelizumab combo trial expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010138","json":"https://secwatch.observer/filing/0001493152-25-010138.json","markdown":"https://secwatch.observer/filing/0001493152-25-010138.md","text":"https://secwatch.observer/filing/0001493152-25-010138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315225010138/0001493152-25-010138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315225010138/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:36:44.918250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}